ArticleIranian journal of pharmaceutical research : IJPR2021
An
Article in Iranian journal of pharmaceutical research : IJPR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Identification and characterization of novel hepcidin mimetics that modulate ferroportin function.Blood red cells & iron · 2026Article
- SIRT1/Nrf2/NF-κB Signaling Mediates Anti-Inflammatory and Anti-Apoptotic Activities of Oleanolic Acid in a Mouse Model of Acute Hepatorenal Damage.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Prevention of the Pro-Aggressive Effects of Ethanol-Intoxicated Mice by Schisandrin B.Nutrients · 2023Article
- The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats.Anatomy & cell biology · 2023Article
- Study on the Role of Schisandrin B in Ameliorating Hepatic Ischemia-Reperfusion Injury by Modulating Hepatocyte Autophagy.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there are no effective treatments for liver diseases. Treatment usually involves controlling complications and supportive care. As liver injuries also affect other organs such as the spleen, kidney, and brain due to their anatomical and physiological relationships, finding an effective treatment is urgently needed. This research aimed to evaluate the therapeutic effect of Schisandrin B (Sch B) in the liver and other organs in thioacetamide (TAA)-intoxicated mice. In this study, mice were exposed to a single intraperitoneal injection of 200 mg/kg TAA to induce hepatitis. Following Sch B (20 mg/kg/day, 28 consecutive days) treatment, biochemistry analysis and histopathological examination of different organs were performed, in addition to western blotting and flow cytometry to evaluate the involvement of inflammasomes and apoptotic proteins. Our results showed that administration of Sch B protected against TAA-induced damages, and it disparately affected inflammasome activation and apoptosis in different organs. Furthermore, Sch B treatment improved organ function, as indicated by the improvement of serum biochemical parameters. Collectively, our findings reveal a beneficial effect of Sch B on different organ damages in mice intoxicated with TAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.